Sorrento anti-SARS-CoV-2 antibodies show encouraging action in preclinical studies (NASDAQ:SRNE)

Sorrento Therapeutics (NASDAQ:SRNE) shares up 6% in premarket, in reaction to preclinical data on COVI-GUARD (STI-1499) and COVI-AMG (STI-2020) antibodies against SARS-CoV-2, and both demonstrated neutralizing activities against SARS-CoV-2 virus infection.In May, it announced that STI-1499 completely inhibited SARS-CoV-2 infection in an in vitro experiment at low concentrationSTI-2020 is an…

Read the full article here

Related Articles